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1094 wileyonlinelibrary.com/journal/dtaAbstract
In the search for improved laboratory methods for the diagnosis of ethylene glycol
poisoning, the in vivo formation of a glucuronide metabolite of ethylene glycol was
hypothesized. Chemically pure standards of the β‐O‐glucuronide of ethylene glycol
(EG‐GLUC) and a deuterated analog (d4‐EG‐GLUC) were synthesized. A high‐perfor-
mance liquid chromatography and tandem mass spectrometry method for determina-
tion of EG‐GLUC in serum after ultrafiltration was validated. Inter‐assay precision
(%RSD) was 3.9% to 15.1% and inter‐assay %bias was −2.8% to 12.2%. The measur-
ing range was 2–100 μmol/L (0.48–24 mg/L). Specificity testing showed no endoge-
nous amounts in routine clinical samples (n = 40). The method was used to analyze
authentic, clinical serum samples (n = 31) from patients intoxicated with ethylene gly-
col. EG‐GLUC was quantified in 15 of these samples, with a mean concentration of
6.5 μmol/L (1.6 mg/L), ranging from 2.3 to 15.6 μmol/L (0.55 to 3.7 mg/L). In five
samples, EG‐GLUC was detected below the limit of quantification (2 μmol/L) and it
was below the limit of detection in 11 samples (1 μmol/L). Compared to the millimolar
concentrations of ethylene glycol present in blood after intoxications and potentially
available for conjugation, the concentrations of EG‐GLUC found in clinical serum
samples are very low, but comparable to concentrations of ethyl glucuronide after
medium dose ethanol intake. In theory, EG‐GLUC has a potential value as a biomarker
for ethylene glycol intake, but the pharmacokinetic properties, in vivo/vitro stability
and the biosynthetic pathways of EG‐GLUC must be further studied in a larger num-
ber of patients and other biological matrices.
KEYWORDS
biomarker, clinical toxicology, ethylene glycol, glucuronide, poisoning1 | INTRODUCTION
Ethylene glycol (EG) or monoethylene glycol (ethane‐1,2‐diol) is an
odorless, colorless, viscous, sweet‐tasting liquid. It is primarily used- - - - - - - - - - - - - - - - - - - - - - - - - -
the Creative Commons Attribution
d, the use is non‐commercial and
blished by John Wiley & Sons Ltdfor industrial production of plastic polymers, polyester fibers, and
films. Other uses include anti‐freeze products for automobiles; cool-
ant, and heat transfer agents for air‐conditioning systems; and de‐icing
fluids along with other niche industrial applications. The world- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
‐NonCommercial‐NoDerivs License, which permits use and distribution in any
no modifications or adaptations are made.
.
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FIGURE 1 Structure of A, ethylene glycol glucuronide (EG‐GLUC); B,
d4‐ethylene glycol glucuronide (d4‐EG‐GLUC)
PEDERSEN ET AL. 1095production of ethylene glycols, of which EG accounts for about 90%
of the total market, was estimated at approximately 35 million tons
in 2016 and its consumption rate is increasing by 5%–6% per year.1
Toxicity after ingestion of EG remains a major concern worldwide
in human clinical toxicology with unintentional exposures in adoles-
cents, children, and the elderly or exposure due to self‐poisonings or
suicide attempts.2 EG poisonings are also described in veterinary
toxicology (livestock, pets).3 To limit poisoning incidents, the bitter‐
tasting compound denatonium benzoate has been added to anti‐
freeze products in many countries. However, in the United States
(USA) implementation of this procedure caused no reduction of oral
EG ingestion cases in humans.4
EG in itself is moderately toxic in humans with an estimated oral
lethal dose of 1.0 to 2.0 g/kg body mass.5 EG is metabolized in vivo
by hepatic enzymatic pathways to glycolic acid and glyoxal, which
are further oxidized into glyoxylic acid and oxalic acid.6 These metab-
olites cause severe metabolic acidosis, central nervous system depres-
sion, and cardio‐pulmonary toxicity. Moreover, calcium oxalate can
precipitate in organs and cause kidney injury.2,6
Treatment can include supportive care, inhibition with either etha-
nol or fomepizole, and in some cases hemodialysis. The classic treat-
ment with ethanol has largely shifted to the use of fomepizole,
which is a competitive inhibitor of alcohol dehydrogenase.7 However,
while the difference in total outcome between the two antidotes has
been debated, ethanol is associated with more frequent adverse
reactions.8
In the USA from 2000 to 2013, 85 891 poisonings with EG were
registered (> 94% acute intoxications), of which 480 (0.6%) had a fatal
outcome.9 In a study from the United Kingdom (UK), covering two
years (2010 and 2012), 1.3% of the total reported telephone enquiries
to the National Poison Information Centre related specifically to
suspected exposure to ethylene glycol or methanol.10 Although ethyl-
ene poisoning is uncommon in the UK, and assays for ethylene glycol
are available on a 24‐hour basis, it was reported that antidote treat-
ment was often provided before analytical results were available.10
Recognition of clinical symptoms of EG intoxication is often diffi-
cult, leaving clinicians − in countries where clinical analysis of EG is
not available (eg, Denmark with 5 million inhabitants) − to rely on sur-
rogate biochemical parameters with insufficient specificity and sensi-
tivity, such as lactate gap,11-13 anion gap14-18 or osmolar gap.19
Generally, well‐organized, fast analytical services and antidote supplies
are needed, since a delay in testing may also cause delays in proper
treatment.20
Poisonings with EG can be diagnosed by quantitative analysis of
EG with gas chromatography (GC), in serum, plasma, post‐mortem
blood and urine.21-35 This may involve different pre‐treatment tech-
niques, like liquid‐liquid extraction (LLE), ultrafiltration, and/or deriva-
tization followed by head‐space sampling, direct thermal desorption,
or injection of extracts on a GC apparatus coupled to flame ionization
(GC−FID) or mass spectrometry (GC–MS). Some methods include
determination of glycolic acid, which correlates well with the degree
of metabolic acidosis.29 Liquid chromatography (LC) has been used
to analyze EG in animals36 or human serum37-40 with variousderivatization techniques. The use of automated, enzymatic screening
assays for EG or glycolic acid has also been implemented.41-45 Such
methods may be used for screening tests to rule out EG poisoning.
However, both GC−FID and enzymatic methods may suffer from
interference with other alcohols or glycols, for example 2,3‐butanediol
and propylene glycol.45,46 Thus, to exclude these rare false positive
screening results GC–MS may be used as a confirmatory reference
method. Recently, an approach that employs liquid chromatography–
tandem mass spectrometry (LC–MS/MS) with detection of ethylene
glycol as a cluster ion was published; however, this method has not
been evaluated in a clinical study.47
Following the implementation of high‐performance LC–MS/MS as
a routine apparatus in bioanalytical laboratories, analysis of phase II
metabolites of medical drugs and illicit substances has gained impor-
tance in clinical and forensic toxicology.48 This includes the glucuro-
nides and sulfates of small polar molecules, for example ethanol and
γ‐hydroxybutanoic acid in blood, urine and hair.49-52 Ethyl glucuronide
(EtG), formed by glucuronidation of ethanol by uridine diphosphate
glucuronosyltransferases (UGTs), has proved suitable as a direct bio-
marker for ethanol consumption.53
However, so far the glucuronides of two of the most important
alcohols in clinical toxicology, methanol and EG, have not been inves-
tigated. In the search of improved laboratory methods for diagnosis of
EG poisoning, the in vivo formation of a glucuronide metabolite of EG
was hypothesized. Chemically pure standards of the β‐O‐glucuronide
of EG (EG‐GLUC) and a deuterated analog for use as internal standard
(IS) (d4‐EG‐GLUC) were synthesized. An LC–MS/MS method for quan-
titative determination of EG‐GLUC in serum after ultrafiltration was
developed and validated. For a proof‐of‐concept of in vivo formation
of EG‐GLUC, authentic clinical samples from confirmed toxicology
cases were analyzed for EG‐GLUC.2 | METHODS
2.1 | Materials and reagents
The β‐O‐glucuronide of ethylene glycol (EG‐GLUC) and a correspond-
ing deuterium‐labeled analog (d4‐EG‐GLUC) was synthesized at the
Department of Drug Design and Pharmacology, Faculty of Health
and Medical Sciences, University of Copenhagen by an approach sim-
ilar to that reported previously (Figure 1).54 The Supporting
1096 PEDERSEN ET AL.Information details the method of synthesis and full characterization
with high‐resolution mass spectrometry (HRMS) and nuclear magnetic
resonance (NMR) spectroscopy. The EG‐GLUC contained an impurity
of 8 mol% 3‐hydroxy‐propanoic acid; the d4‐EG‐GLUC substance
contained 10 mol% 3‐hydroxy‐propanoic acid. During preparation of
the stock solutions described in the next paragraph, no correction fac-
tor was used for this impurity.
Stock solutions (10 mmol/L) of EG‐GLUC and d4‐EG‐GLUC
(10 mmol/L) were prepared in purified water and stored at −20°C.
The EG‐GLUC stock solution was used to prepare quality control sam-
ples (QC) in serum. The IS aqueous working solution of d4‐EG‐GLUC
was 200 μmol/L. Methanol was LiChrosolv LC–MS hypergrade
(Merck, Darmstadt, Germany). Formic acid (99%) was HiPerSolv LC–
MS grade (VWR International, Søborg, Denmark). Purified water (18
MΩ) was generated in an ELGA LabWater CENTRA® RDS system
(High Wycombe, UK). Other reagents were of analytical grade.2.2 | Liquid chromatography−tandem mass
spectrometry
The LC–MS/MS system used was a 6460 triple‐quadrupole mass
spectrometer (Agilent Technologies, Palo Alto, CA, USA) with a
Jetstream electrospray ion source, operated at unit resolution. The
chromatographic system consisted of an Agilent 1200 binary pump,
a 1200 SL well‐plate autosampler and a 1200 column department.
Separation was performed on a Kinetex Biphenyl 100A column
(100 × 3 mm), particle size 2.6 μm (Phenomenex, Macclesfield, UK).
Flow rate was 550 μL/min using the mobile phases: (A) 0.1% formic
acid in purified water; and (B) 0.1% formic acid in methanol. Gradient
elution was as follows: 2% B for 0.5 minutes, then up to 95% B in
4.5 minutes, 95% B for 3 minutes followed by equilibration at initial
conditions for 2 minutes. Total run time was 9 minutes and the columnTABLE 1 Multiple reaction monitoring (MRM) parameters and tolerance
Compound Precursor Ion m/z Fragment Ion m/z Collision Energy
EG‐GLUC 237.1 85 10
113 10
99 10
75.3 10
57 20
55 30
45 30
43 25
d4‐EG‐GLUC 241.1 75 10
113.2 10
94.8 15
85 15
71 20
57 20
55.2 30
43 20
*values show inter‐batch variability.temperature was maintained at 40°C. Autosampler injection volume
was 1 μL and the sample tray was kept at 20°C.
The electrospray source parameters were as follows: capillary volt-
age: 3500 V; declustering potential 120V; nitrogen gas flow: 8 L/min;
nitrogen gas temperature: 350°C; sheath gas flow: 8.5 L/min; sheath
gas temperature: 375°C; nozzle voltage: 400 V; nebulizer pressure:
25 p.s.i.
Declustering potential and individual collision energies for EG‐
GLUC and d4‐EG‐GLUC were optimized manually in flow injection
mode. Multiple reaction monitoring (MRM) was performed in negative
ionization mode (−ES) using the deprotonated precursor ions [M−H]−
for both EG‐GLUC (m/z 237.1) and d4‐EG‐GLUC (m/z 241.1) (Table 1).
The MRM transitions for EG‐GLUC, m/z 237.1 →m/z 85, and for d4‐
EG‐GLUC, m/z 241.1 → m/z 75, was used for quantification. MRM
dwell time was fixed at 40 ms. Sample concentrations were deter-
mined from peak‐area ratios of EG‐GLUC to d4‐EG‐GLUC by refer-
ence to a calibration curve. Data acquisition and post‐analysis was
performed with MassHunter™ software, version B.04.01 (Agilent
Technologies, Palo Alto, CA, USA). Figures 2 and 3 were directly
exported to PDF‐format from MassHunter software and annotated
using Adobe InDesign. Figure 4 was constructed using mass spectral
data export to SigmaPlot 12.0 and annotated using Adobe InDesign.
The identification of EG‐GLUC in clinical samples was approved in
case of correct assigned retention time (tolerance ±2.5%) and from
MRM data, when the relative ratios for seven qualifying ions,
expressed as a percentage of the intensity of the most intense transi-
tion, matched with the mean values determined in calibrators in the
same batch. Acceptable tolerances are shown in Table 1. Performance
criteria for qualifying ions described in an EU directive55 as well as in
technical documents used by laboratories accredited by the World
Anti‐Doping Agency (WADA),56 were used. There is a general consen-
sus in endogenous compound identification (by environmental and
food analysis, doping control, etc.) for using different acceptance tol-
erances (range: 20%–50%) for qualifying ions depending on thes for qualifying ion ratios
(V) Qualifying Ion Ratio (%) * Qualifying Ion Ratio Tolerance (%)
Used for quantification ‐
60.5 ± 20
13.6 ± 30
65.9 ± 20
31.2 ± 25
23.9 ± 25
8.7 ± 50
6.4 ± 50
Used for quantification ‐
63.4 ± 20
11.3 ± 30
109 ± 20
20.4 ± 25
35.1 ± 25
28.5 ± 25
6.4 ± 50
FIGURE 2 Negative ionization electrospray product ion spectra of ethylene glycol glucuronide (EG‐GLUC), [M−H]− = m/z 237.1, at different
collision energies (CE): A, 5 V; B, 20 V; C, 35 V. Declustering potential: 120 V
PEDERSEN ET AL. 1097relative ion abundances (% of base peak). These criteria were also
evaluated and found applicable for confirmatory drug analysis in
plasma and urine by LC–MS/MS.572.3 | Evaluation of internal standard purity
Prior to method development, initial testing of a stock solution of d4‐
EG‐GLUC (1 mmol/L), using the LC–MS/MS method described in
section 2.2, showed less than 0.63% content EG‐GLUC calculated
from the peak area ratios. This trace amount of EG‐GLUC is accept-
able for use of d4‐EG‐GLUC as IS.2.4 | Calibration standards and quality controls
2.4.1 | Serum calibrators
Serum calibrators (n = 6) were prepared by spiking aqueous working
solutions of EG‐GLUC into serum obtained from a large blood donor
pool (n = 1000), prepared for quality control materials at the Depart-
ment of Biochemistry, North Denmark Regional Hospital. The serumwas kept at −80°C until use. The final calibrator concentrations used
for method validation were 100, 50, 25, 10, 5, and 2 μmol/L.2.4.2 | Calibration curve and batch setup
Calibration curves were based on least‐squares linear regression
(Y = aX + b), not forced through zero, with no weighting factor. Every
batch also contained a zero sample (matrix processed with IS) and a
blank sample (matrix processed without IS). For the batches of clinical
serum samples (with unknown concentrations), each sample was sep-
arated by a blank sample.2.4.3 | Spiked quality control samples (QC)
Spiked serum samples were prepared as described for serum calibra-
tors (section 2.4.1), including a QC sample at 250 μmol/L for dilution
integrity testing. The QC samples were used during method validation
and as QC samples during analysis of clinical samples. They were kept
at −20°C until use.
FIGURE 3 Negative ionization electrospray product ion spectra of the deuterated internal standard d4‐ethylene glycol glucuronide (d4‐EG‐
GLUC), [M−H]− = m/z 241.1, at different collision energies (CE): A, 5 V;B, 20 V; C, 35 V. Declustering potential: 120 V
1098 PEDERSEN ET AL.2.4.4 | Aqueous calibrators
A series of aqueous calibrators (n = 9) were prepared by spiking aque-
ous working solutions of EG‐GLUC into purified water. The concentra-
tions were 1000, 500, 250, 200, 100, 50, 25, 10, 5, 2, and 1 μmol/L.2.5 | Clinical toxicology samples
Anonymized, authentic clinical samples (n = 31) from patients with
confirmed EG intoxications were provided by CHU Ste‐Justine, Mon-
treal (Quebec, Canada). The samples were serum aliquots from routine
blood sampling taken at the admission of patients suspected of ethyl-
ene glycol intoxication. No extra blood samples were retrieved for the
present project. It was not registered if the patients had received
treatment with fomepizole. For samples #15 to #31, the concentra-
tions of EG are available. Due to the anonymization, age, gender,
and dates of sampling are not available for this study. However, no
samples were stored more than a year from the time of sampling to
date of analysis. The samples were shipped frozen (on dry ice) to the
Department of Clinical Biochemistry, North Denmark Regional Hospi-
tal, and stored at −80°C until analysis. According to Danish Law onScientific Research # 593 of June14, 2011, § 14,3 anonymized clinical
samples can be studied without approval of the Human Ethics Com-
mittee. The EG‐GLUC results had no influence on the handling and
clinical care of patients.2.6 | Sample preparation by ultrafiltration
Sample preparation was identical for calibrators, spiked quality con-
trols, and clinical samples. IS working solution (10 μL) and serum sam-
ple (250 μL) was added directly into an Amicon Ultra centrifugal filter
device (0.5 mL) with a 30 kDa nominal molecular weight limit cut‐off
(Millipore/Merck, Darmstadt, Germany). After vortex mixing for 2 sec-
onds, the tube was centrifuged for 30 minutes at 12 000 × g. Then
100 μL of ultrafiltrate was transferred to a 300 μL fixed insert vial
(Chromacol, Langenwehe, Germany), capped, and placed in the
thermostatted autosampler at 20°C until analysis.2.7 | Sample preparation by protein precipitation
To evaluate method specificity and the final sample preparation tech-
nique by ultrafiltration, protein precipitation was performed ad hoc by
FIGURE 4 Extracted multiple‐reaction monitoring (MRM) ion chromatograms for LC–MS/MS analysis of EG‐GLUC in serum. A, Target ion m/z
237.1 → m/z 85 (EG‐GLUC) and m/z 241.1 → m/z 75 (d4‐EG‐GLUC) in a serum calibrator (2 μmol/L); B, target and qualifying ions for EG‐GLUC
(overlaid) in a serum calibrator at LOQ (2 μmol/L). The asterisk (*) shows closely eluting, unknown endogenous compounds detected in most
transitions; C, zero sample with IS and target/qualifying ions for EG‐GLUC (overlaid); D, blank serum sample without IS and target/qualifying ions
for EG‐GLUC overlaid; E, target ion m/z 237.1 → m/z 85 (EG‐GLUC) and m/z 241.1 → m/z 75 (d4‐EG‐GLUC) in a clinical sample (#12) at
5.67 μmol/L; (F) target and qualifying ions for EG‐GLUC (overlaid) in a clinical sample (#12). Plots A, C, D, E, and F are in the same y‐axis scale. Plot
B is in half y‐axis scale
PEDERSEN ET AL. 1099the following procedure: Serum (100 μL) was added to an Eppendorf
tube (1.5 mL) with 400 μL cold acetonitrile, mixed for 30 seconds
and centrifuged 10 minutes at 12000 × g.3 | METHOD VALIDATION
Method performance was validated according to the key principles in
Guidance for Industry, Bioanalytical Method Validation.58 This guideline
sets out specific method validation criteria for LC–MS/MS analysis of
drugs or metabolites in biological matrices. It was supplemented by (a)characterization of the custom synthesized standard of EG‐GLUC
(Supporting Information), (b) evaluation of the IS purity, and (c)
extended acceptance criteria for using qualifying ions for unambigu-
ous identification of EG‐GLUC in clinical samples (Table 1).3.1 | Selectivity/specificity
Method selectivity was assessed by analyses of (a) anonymized, blood
donor serum aliquots (n = 20), obtained within one week after sam-
pling from the local blood bank; (b) anonymized serum samples
1100 PEDERSEN ET AL.(n = 20), randomly selected among routine clinical samples at the
Department of Clinical Biochemistry, North Denmark Regional Hospi-
tal. The sampling was performed in polypropylene collection tubes
without additives. All samples were kept at 4–8°C for up to 2 weeks
prior to analysis. During testing of specificity, samples were analyzed
for EG‐GLUC and isobaric interferences after both protein precipita-
tion and ultrafiltration. Standards of the ethanol conjugates − EtG
and ethyl sulfate (EtS) − at 2000 ng/mL in ultrafiltrate were injected
to evaluate interfering effects.3.2 | Evaluation of sample preparation method
The sample preparation by ultrafiltration was evaluated at three con-
centration levels (in both aqueous and serum samples) with spiking
of the IS to the final ultrafiltrate. The recovery of EG‐GLUC was quan-
tified using aqueous calibrators (because ultrafiltrated serum calibra-
tors would mask the effect of protein binding). Chromatograms were
evaluated for samples using ultrafiltration versus protein precipitation.3.3 | Linearity and calibration
Linearity was evaluated by calibration curve data from different
batches (n = 6). Linearity was expressed by the correlation coefficient
(r), with the acceptance criterion r > 0.999. The repeatability of calibra-
tion was assessed by the relative standard deviation (%RSD) of the
calibration curve slopes and the Y‐axis intercept values.3.4 | Precision and accuracy
Accuracy and precision was evaluated with at least four QC concen-
tration levels. Intra‐assay data was obtained by five determinations
per concentration level within one batch. Intermediate bias and preci-
sion data were obtained from batches on five different working days.
Precision was expressed as the relative standard deviation (%RSD).
Accuracy was expressed as %bias (recovery% − 100), defined as
recovery% = [measured concentration/spiked concentration ×
100%]. The acceptance criteria for precision and accuracy was
%RSD < 15 and %bias ±15, except at the limit of quantification (LOQ).3.5 | Limit of quantification/limit of detection
The LOQ was the lowest concentration that could be analyzed within
%RSD < 20 and %bias ±20, and using all qualifying ions within the
acceptance criteria shown in Table 1. The limit of detection (LOD)
was calculated as mean ± 3 × standard deviations (SD) in zero samples.
Signal‐to‐noise was also calculated for LOQ and LOD.3.6 | Carry‐over
The effect from carry‐over was assessed by analyzing a QC sample
(250 μmol/L) followed by a blank (with no IS), and was reported inpeak area‐%. Carry‐over was also evaluated in zero samples during
method validation batches and clinical samples.3.7 | Dilution integrity
To test dilution integrity, a QC sample (250 μmol/L) was diluted 1:5,
1:10, 1:25, and 1:50 with blank serum prior to analysis. The average
%bias and %RSD were reported. The acceptance criterion was 15%.3.8 | Evaluation of matrix effects
Quantitative matrix effects (ion suppression of signals) were calculated
by the ratio of quantification ion intensities (m/z 237.1 → m/z 85) in
equimolar aqueous calibrators relative to serum calibrators, and
expressed in percentages.
Qualitative matrix effects were evaluated by a post‐column infu-
sion experiment using a single‐syringe infusion pump (Cole Palmer,
Vernon Hills, IL, USA) delivering a fixed amount of EG‐GLUC per time.
Concentration in the final eluent was 25 μmol/L. Blank serum ultrafil-
trate (1 μL) was injected and the total ion chromatogram of the LC–
MS/MS method was monitored.3.9 | Stability
Stability studies were limited by the relatively small amount of sub-
stance available for the study (5.37 mg), where preparation of new
stock solutions for each stability batch was not possible. Thus, all sta-
bility testing results were calculated relative to the serum calibrators
prepared from a single stock solution which was kept at −20°C. The
solid standard substance of EG‐GLUC was assumed to be fully stable
at −80°C. In all stability experiments , EG‐GLUC was considered sta-
ble if the deviations were within ±15%, which is the method validation
criterion for bias.3.9.1 | Stability toward heating and forced acidic and
alkaline hydrolysis
Clinical toxicology laboratories may use chemical hydrolysis during
pre‐treatment of samples. Hence, the stability toward simple heating
and acidic/alkaline hydrolysis was tested by the following procedure:
Aqueous calibrators (100 μmol/L) were incubated at (a) 60°C or
100°C without hydrolyzing reagents; (b) 60°C in 4 M HCl; or 100°C
in 8 M HCl; (c) 60°C in 4 M NaOH; or 100°C in 8 M NaOH;. The incu-
bation time was 15 minutes. After cooling, the acidic or alkaline solu-
tions were neutralized with NaOH or HCl, respectively. All samples
were adjusted to the equal final volumes, spiked with IS, and analyzed
with LC–MS/MS. Incubation at 100°C was performed in a pressure‐
cooking device. Degradation was calculated relative to an aqueous cal-
ibrator, kept at room temperature during the experiments.
PEDERSEN ET AL. 11013.9.2 | In‐sampler stability
A series of QC serum samples was left in the thermostatted
autosampler at 20°C for four days, reanalyzed and quantified with a
freshly prepared calibration curve. The difference was calculated in
percentage of the initial result.3.9.3 | Long‐term stability
The stability of EG‐GLUC in serum at 4°C was assessed at 4, 14, 27,
and 155 days. The influence of storage at −20°C for two months
including freeze–thaw cycles (n = 3) were evaluated in a single QC
sample (100 μmol/L). Results within ±15% from spiked concentrations
were considered acceptable.4 | RESULTS AND DISCUSSION
4.1 | Mass spectrometry
EG‐GLUC detection was performed in negative electrospray ionization
mode (−ES). No molecular ion [M+H]+ was observed in full scanning
+ES mode, probably due to high sodium ion affinity of the glucuronide
as only this adduct ion [M+ Na]+ was observed. The –ES product ion
mass spectra of deprotonated EG‐GLUC, m/z 237.1 and deprotonated
d4‐EG‐GLUC, m/z 241.1 are shown in Figures 2 and 3. Due to the
absence of fragment ions with +4 (originating from the deuterium‐
labeled aglycone), it was concluded that most peaks originate from
the electrophilic glycosyl moiety. The ions m/z 75, 85, 95 and 113
have been reported in the product ion spectra of other glucuro-
nides59,60 and are part of a general fragmentation pattern observed
for O‐glucuronides.614.2 | Liquid chromatography
LC was performed in gradient mode using a biphenyl column that can
separate the positional isomers of, for example, morphine glucuro-
nides. With a low pH (approximately 2.6) in the mobile phase, EG‐
GLUC eluted as a symmetric peak with the retention time (RT) 1 min-
ute, as seen in the chromatograms of a calibrator and a clinical sample
(Figure 4). RSD% for RT in samples with measured EG‐GLUC (above
LOQ) was below 1%. EG‐GLUC and EtG co‐elute during analysis, but
there is no interference in the measurements of the two glucuronides.
Injection of serum ultrafiltrate versus the analyte dissolved in the
mobile phase had a significant matrix effect on retention time, as
EtG elutes approximately 0.5 minutes later in aqueous solution or in
urine compared to ultrafiltrate using identical LC parameters. Given
the minor differences in chemical structure between EG‐GLUC and
EtG, separation by reversed‐phase chromatography may be challeng-
ing. The retention (capacity) factor for EG‐GLUC was estimated to
0.25, which shows poor retention.4.3 | Evaluation and choice of sample preparation
method
Although plasma protein binding of some drug glucuronides have been
reported,62 little is known about the protein binding of small, hydro-
philic compounds and their glucuronides. Thus, there are no reports
on plasma protein binding of EtG, which is close to EG‐GLUC in struc-
ture.63 Generally, ether O‐glucuronides are more stable and show
higher stability than the electrophilic acryl‐glucuronides, which may
undergo intra‐molecular rearrangement and irreversible, covalent
binding to plasma proteins.64 For small polar compounds with no pro-
tein binding, like methylmalonic acid, ultrafiltration can be used for
sample pre‐treatment prior to analysis by LC.65 Ultrafiltration is a rel-
ative simple technique, which only depends on access to a high‐speed
centrifuge, normally available in a clinical laboratory. No disadvantages
were observed for ultrafiltration as a pre‐treatment tool during the
present study: It is a solvent‐free isolation technique with a low dilu-
tion factor only due to spiking of the internal standard with little or
no effect on chromatography column lifetime. Protein precipitation
with acetonitrile has the disadvantage of a high dilution factor prior
to analysis. Chromatograms in this study were characterized by more
noise and interfering peaks for protein precipitation compared with
ultrafiltration.4.4 | Method validation results
Method precision and accuracy results are shown inTable 2 and other
validation parameters and results are summarized inTable 3. In section
4.4.1 to 4.4.6 the critical parameters are discussed in detail.4.4.1 | Selectivity/specificity
Specificity testing showed no endogenous amounts above LOD in
routine clinical samples used for specificity testing (n = 40). Further-
more, EG‐GLUC was not detected in the serum pool used to prepare
calibrators and QCs and blank samples. At low concentrations,
unknown endogenous peaks eluting prior to EG‐GLUC was observed
in all samples (Figure 4). However, the chromatographic resolution
was suitable and did not introduce bias on the determination of con-
centrations in the final measuring range. Furthermore, EtG/EtS did
not cause interference during detection of EG‐GLUC.4.4.2 | Linearity and calibration
Standard curves of both aqueous and serum calibrators showed linear-
ity up to at least 100 μmol/L with correlation coefficients (r2) above
0.99. The average calibration curve slopes in these two matrices were
0.159 (n = 3) and 0.175 (n = 8), for aqueous and serum calibrators
respectively. The serum calibration curves were reproducible (slope
%RSD = 4.0) over a time period of eight months.
TABLE 2 Method validation data (n = 5) for quantification of EG‐GLUC in serum
Sample
Concentration Intra‐assay Precision Intermediate Precision
μmol/L μg/mL RSD% Bias (%) RSD% Bias (%)
Spiked serum 100 23.8 4.0 +1.6 4.2 +1.8
50 11.9 3.1 − 0.8 4.4 − 2.8
10 2.38 8.5 +2.5 3.9 − 1.8
2 0.48 7.5 +1.7 15.1 + 12.2
1 0.24 7.3 − 35.4 Not tested Not tested
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The intra‐assay precision (%RSD) was 3.9 to 15.1% and %bias in the
range − 2.8 to 12.2%, which is considered acceptable for bioanalytical
methods.58 LOQ was 2 μmol/L, and LOD was calculated to 0.1 μmol/
L. The signal‐to‐noise at LOQ (n = 5) was in the range 35–53 and for
LOD (n = 5) in the range 11–21. In theory, the LOD also depends on
the minor impurity of EG‐GLUC in the IS. However, the IS amount
used during sample preparation was not a limiting factor for LOD in
this study. Above LOQ, all qualifying ion ratios for EG‐GLUC in clinical
samples were within acceptance criteria (Table 1). In a few single injec-
tions, the response ratios of two qualifying ions for IS (m/z 57 and m/z
94.8) were outside the range. This was of no importance for the
results of the present study. The qualifying ions with ratios below
10% and tolerances of ±50% could be excluded in further research
methods, but all qualifying ions were used herein to maximize the
identification power in this first report on EG‐GLUC in a biological
sample.4.4.4 | Dilution integrity
All samples validated for dilution integrity showed acceptable %bias
and RSD% below 15%.4.4.5 | Matrix effects
Due to the low retention of glucuronides to the biphenyl column, EG‐
GLUC elutes in the region where matrix effects are expected. Matrix
effects were estimated quantitatively by comparing ion intensities of
serum calibrators to aqueous calibrators with equimolar concentration.
These results showed up to 49.4% ion suppression (Table 3). A post‐
infusion ion‐suppression experiment (Figure 5) showed that EG‐GLUC
elutes in a zone where ion suppression is evident. However, it is gen-
erally assumed that the isotope‐labeled, co‐eluting internal standard
(d4‐EG‐GLUC) compensates for the alteration in signal, thereby mini-
mizing matrix and ion‐suppression effects on quantification results.
However, ion suppression has an impact on the LOD. The variation
in IS response for the batches in this study, expressed as RSD%, was
below 15, which was considered acceptable. In conclusion, ion‐sup-
pression effects were not considered to be a problem for the use of
the present method and for the validity of the obtained results.4.4.6 | Stability
Effect of acidic or alkaline hydrolysis
During forced degradation in 8 M HCl by incubation in a pressure
cooker, EG‐GLUC was degraded completely, while 87% of EG‐GLUC
was recovered after autoclaving in 8 M NaOH.
Simple heating at 60°C or in a pressure cooker without hydrolyzing
reagents; and with both 4 M HCl and 4 M NaOH did not affect the
recovery of EG‐GLUC (Table 3).
In‐sampler stability
Samples were stable for at least 4 days at 20°C in the autosampler as
the differences in pre‐ and post‐analysis was comparable to inter‐
assay bias (Table 3). The maximum difference‐% in a sample was 9.3.
Long‐term stability
Serum calibrators with EG‐GLUC (100, 50, 25 and 10 μmol/L) were
stable for a minimum of 155 days at 4–8°C and for a minimum of
two months at −20°C including freeze–thaw cycles (n = 3). Based on
these data and the forced degradation experiment, EG‐GLUC is con-
sidered stable in both aqueous solution and serum under standard lab-
oratory working and storage conditions.4.5 | Clinical sample results
The method was used to analyze authentic clinical serum samples
(n = 31) from patients intoxicated with ethylene glycol. EG‐GLUC
was quantified in 15 of these samples, with a mean concentration of
6.5 μmol/L (1.6 mg/L), ranging from 2.3 to 15.6 μmol/L (0.55 to
3.7 mg/L). In 5 samples, EG‐GLUC was detected below LOQ and in
11 samples EG‐GLUC concentrations were below LOD (Table 4).
There was no meaningful correlation between EG and EG‐GLUC con-
centrations and statistical analysis on these data were not pursued.4.6 | Potential use of EG‐GLUC in bioanalysis
The glucuronidation in vivo of small aliphatic alcohols and carboxylic
acids is complex and not yet fully understood. The ether glucuronide
of an alcohol differs in terms of stability from the ester (acyl) glucuro-
nide of a carboxylic acid, which can undergo rearrangement processes
into isomers.64
TABLE 3 Summary of method validation data
Validation of the 7‐point calibration curve (inter‐assay, n = 7)
Slope (mean ± S.D.) 0.173256 ± 0.004187
C.V. (%) Slope 2.42
r (mean ± S.D.) 0.999645 ± 0.000326
Intercept (mean ± S.D.) 0.050863 ± 0.033657
Limits of quantification and detection
Upper limit of quantification (μmol/L) 100
Lower limit of quantification (μmol/L) 2
Limit of detection (μmol/L) 1
Carry‐over
Calibrator 250 μmol/L to blank sample (no IS), peak area‐% 0,026%
In blanks in batches with clinical samples < LOD
Stability toward heating and acid/alkaline hydrolysis (15 min)
Recovery after heating at 60°C; or incubation in a pressure cooker 104%,;102%
Recovery after heating at 60°C with 4 M HCl; or 4 M NaOH 113%; 111%
Recovery after incubation in a pressure cooker with 8 M HCl 0%
Recovery after incubation in a pressure cooker with 8 M NaOH 87%
In‐sampler stability (4 days at 20°C)
Calibrators (kept at 18 days in a fridge prior to the experiment), mean difference‐% and range 1.6 (−2.6 to 9.3)
Calibrators (kept at 7 days in a freezer prior to the experiment), mean difference‐% and range 3.9 (−3.5 to 7.9)
Long‐term stability
Serum calibrators (100, 50, 25, and 10 μmol/L), 155 days at 4–8 °Crecovery‐% mean and range 102 (98.3–108)
Serum calibrator (100 μmol/L) at −20°C, freeze–thaw cycles (n = 3) for two months, final recovery 96.4%
Ion suppression (matrix effect)
Serum calibrators/aqueous calibrators, mean response‐% and range 40.9 (30.3 to 49.4)
Recovery‐% after ultrafiltration *
Aqueous calibrators (12.5; 25 and 100 μmol/L), mean and range 97.5 (94.8 to 100)
Serum calibrators (12.5; 25, 50 and 100 μmol/L), mean and range 110.5 (103.5 to 118.8)
*quantified with calibration curve from aqueous calibrators (see text for explanation).
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was synthesized, as this is the sole product formed in vivo by UDP‐
glucuronosyltransferase.
The most important prospect of EG‐GLUC is the potential to use
the metabolite as a biomarker for EG intoxication, in analogy with
EtG, which is used as a routine biomarker for ethanol consumption.53
This would require a comprehensive clinical evaluation of patients
involving analysis of various biological matrices. Compared to the mil-
limolar concentrations of EG present in blood after intoxications and
potentially available as substrate for conjugation, the concentrations
of EG‐GLUC found in clinical samples were very low (Table 4).
4.6.1 | Comparison with EtG and EtS
Here, a comparison with ingested amounts of alcohol versus serum
concentrations of EtG and EtS is relevant. In a study of healthyvolunteers, after intake of a single ethanol dose (44–90 g), EtG did
not exceed 16.6 μmol/L (3.7 mg/L) and EtG in serum peaked 2–
3.5 hours later than ethanol and could still be determined up to 8 hours
after complete ethanol elimination.66 There was an exponential
decline in EtG with a half‐life of 2–3 hours.
It is important that concentrations of EG and EtG do not peak at
the same which was also shown in a kinetic model of the pharmacoki-
netics of EtG in humans based on data from drinking experiments.67
In a kinetic study of EtG in heavy drinkers (n = 14) during detoxifi-
cation, EtG in serum was in the range 0.45 to 27 μmol/L (0.1 to
5.9 mg/L) and EtS in serum was in the range 0.79 to 8.6 μmol/L (0.1
to 1.9 mg/L), except for one subject with outlying EtG and EtS con-
centrations caused by serious renal and hepatic disease. The last eth-
anol intake was 122 g median (range 25 to 376 g).68
In a pharmacokinetic study by Halter et al of EtG formation after
medium doses of ethanol (0.5 to 0.78 g ethanol/kg body mass), for
FIGURE 5 Post‐column infusion experiment to determine matrix
effects (ion suppression/enhancement). Concentration of EG‐GLUC
in eluent after infusion: 25 μmol/L. A, Total ion chromatogram (TIC) in
counts‐per‐second (cps) after injection of blank serum ultrafiltrate
(two injections overlaid). B, Total ion chromatogram (TIC) of EG‐GLUC
standard (25 μmol/L). C, Dotted line shows the retention time of EG‐
GLUC
TABLE 4 Analysis of EG‐GLUC in clinical serum/plasma samples
from patients with confirmed ethylene glycol intoxications (n = 31)
Sample #
EG EG‐GLUC
mmol/L* g/L μmol/L mg/L
1 n.a. n.a. 3.4 0.81
2 n.a. n.a. 7.2 1.7
3 n.a. n.a. 2.3 0.55
4 n.a. n.a. 4.9 1.2
5 n.a. n.a. 3.0 0.72
6 n.a. n.a. < 2 < 0.48
7 n.a. n.a. 15.6 3.7
8 n.a. n.a. 13.4 3.2
9 n.a. n.a. 12.6 3.0
10 n.a. n.a. 14.8 3.5
11 n.a. n.a. < LOD < LOD
12 n.a. n.a. 5.7 1.4
13 n.a. n.a. < 2 < 0.48
14 n.a. n.a. < 2 < 0.48
15 75.9 4.7 < LOD < LOD
16 18.2 1.1 2.8 0.67
17 12.2 0.76 2.5 0.60
18 4.0 0.25 < 2 < 0.48
19 1.2 0.074 < LOD < LOD
20 3.3 0.21 < LOD < LOD
21 8.7 0.54 < 2 < 0.48
22 17.9 1.1 < LOD < LOD
23 3.7 0.23 < LOD < LOD
24 2.0 0.12 < LOD < LOD
25 1.2 0.075 < LOD < LOD
26 2.3 0.14 2.2 0.52
27 3.1 0.19 < LOD < LOD
28 3.8 0.24 < LOD < LOD
29 22.4 1.4 < LOD < LOD
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concentrations of EtG peaked in the range 1.2 to 4.9 μmol/L, and
decreased to 1–2 μmol/L after 10–11 hours.69 The LC–MS/MS
method used by Halter et al has an LOQ of 0.45 μmol/L for EtG, with
a 10‐fold higher injection volume as used in the present study.
Thus, the serum concentrations of EG‐GLUC found in the present
study are comparable to the peak and ranges of EtG or EtS in serum
expected after intake of moderate to high ethanol doses. The low or
missing EG‐GLUC concentrations could partly be explained by early
sampling, also taken into consideration that concentrations below
1 μmol/L are not detected by the applied method.30 5.6 0.35 2.4 0.57
31 14.5 0.90 4.3 1.0
*EG analysis by GC‐FID available, LOQ: 1 mmol/L (0.062 g/L).
n.a. = not available.4.6.2 | The prospects of urine analysis
Studies on EtG, EtS, and γ‐hydroxybutanoic acid glucuronide (GHB‐
GLUC) have shown at least 100 times higher peak concentrations of
glucuronides in urine versus plasma.70,71 For qualitative analysis of
EG‐GLUC to report whether the patient has ingested EG, or for deter-
mination of chronic exposure, urine may be a more suitable sample
matrix, although serum/plasma or whole blood is normally preferred
for clinical toxicology analysis of EG. For urine analysis, a suitable
cut‐off concentration would be needed, for example based on EG‐
GLUC levels related to occupational exposure to EG. In a study of
Canadian aviation workers exposed to de‐icing fluid, EG was mea-
sured in next‐morning urine samples up to 129 mmol/mol creatinine
without indication of important health effects from the exposure.72Unfortunately, urine samples from clinical toxicology or working
places were not available for the present study.4.6.3 | Other conjugates of EG
The role of sulfate conjugation in the metabolism of EG has not been
investigated and a reference standard of this compound (4‐(sulfooxy)
ethylene glycol, EGS) is not commercially available. Therefore, at pres-
ent it is unknown whether a sulfate of EG is present in clinical
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ble by a method previously reported by Mehling et al by treating EG
with sulfurtrioxide pyridine complex.73 However, due to the presence
of two hydroxy groups in EG, o‐ and di‐sulfonated as well as
unreacted EG is likely to be obtained. Moreover, the stability of EGS
is likely to be poor because the sulfonated alcohol represents a good
leaving group, which by intramolecular ring closure would expel sul-
fate to form ethyleneoxide.
Formation of double conjugates in humans by UDP glucuronosyl-
transferase of both the acyl‐ and aryl types have been reported for,
for example morphine (morphine 3,6‐diglucuronide),74 bilirubin (biliru-
bin diglucuronide)75 and bisphenol‐A (mono‐ and di‐glucuronides,
mono‐ and di‐sulfates).76 Polyphenols may contain mixed sulfates/glu-
curonide conjugates,77 and this may theoretically also be the case for
glycols.
It may be possible to qualitatively search for the presence of
disulfates, diglucuronides, or mixed sulfate/glucuronide metabolites
of ethylene glycol in biological samples by non‐targeted analysis with
high resolution mass spectrometers. However, it was outside the
scope of the present study, where the clinical sample amount was
limited and none of these metabolites are available as chemical
standards.4.7 | Limitations of the study
The present study was solely aimed at the proof‐of‐concept for the in
vivo formation of EG‐GLUC and the authors do not make any claims
about the suitability of EG‐GLUC as a biomarker in serum for ingested
EG. In fact, this aspect does not look promising for serum as a sample
matrix, based on the data obtained by the LC–MS/MS method used in
this study. Further research of EG‐GLUC in serum should optimize the
LC–MS/MS method sensitivity in order to detect sub‐micromolar
concentrations.
The choice of analytical column was based on our experience with
high robustness and reproducibility of the biphenyl phase in routine
determination of other glucuronides, including direct injection of bio-
logical specimen (urine, serum ultrafiltrate). However, the retention
of these very polar compounds is poor, and matrix effects can cause
bias and impression if co‐eluting, isotope‐labeled ISs are not used.
More polar column materials or hydrophilic interaction chromatogra-
phy (HILIC) could theoretically be promising regarding matrix effects,
but this approach was not pursued in the present study. In addition,
we believe that HILIC would be better suited for protein precipitation
with acetonitrile rather than for direct injection of serum ultrafiltrate.
The present study shows 11 clinical samples >(Table 4) where EG‐
GLUC could not be detected. Although the stability testing showed
EG‐GLUC to be stable for at least 155 days at 4–8°C and a minimum
of 2 months at −20°C (including 3 freeze‐thaw cycles), degradation by
enzymes or other hydrolysis mechanisms in serum cannot be excluded
during the total storage period for up to one year in the present study.
Furthermore, it is uncertain whether clinical and medical treatment of
patients may have influenced the formation of EG‐GLUC in vivo.Stock solution and pure solid substance stability was not studied
due to the limited amount of EG‐GLUC synthesized.5 | CONCLUSIONS
We have shown that EG‐GLUC is a hitherto unrecognized metabolite
of EG with a prospective use in analytical toxicology. Methods for
chemical synthesis of reference standards of EG‐GLUC and an iso-
tope‐labeled IS d4‐EG‐GLUC are now available for continued research
in the subject. The LC–MS/MS method − which was developed and
validated specifically for the present study − can be adapted using
fewer qualifying ions and a higher injection volume for routine deter-
mination of EG‐GLUC in serum or other matrices.
To address the potential value of including EG‐GLUC in
bioanalytical methods for diagnosis of EG ingestion, the pharmacoki-
netic properties and the biosynthetic pathways of EG‐GLUC must be
characterized by in vitro system studies, analyses in a larger number
of intoxicated patients, and analyses in other biological matrices,
including a complete profile of all relevant EG metabolites.
If analytical procedures for the determination of EG in blood are
not available for patient‐near testing − and EG‐GLUC is proven useful
as biomarker for EG intoxication − the growing number of clinical bio-
chemical laboratories with access to routine LC–MS/MS apparatus
could analyze EG‐GLUC and ensure faster diagnosis. This could pro-
spectively benefit treatment outcome.
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